Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 1, 2008, Pages 93-95

  Alexander, Sarah ^a   Hopewell, Steve ^b   Hunter, Susan ^b   Chouksey, Akhilesh ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Anaphylaxis; Desensitization; Factor IX; Hemophilia; Immune tolerance; Inhibitors

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DIPHENHYDRAMINE; METHYLPREDNISOLONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RITUXIMAB;

ANAPHYLAXIS; ARTICLE; BLEEDING; CASE REPORT; DESENSITIZATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SCHOOL CHILD; SKIN TEST; TREATMENT RESPONSE; URINALYSIS; URTICARIA;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; DESENSITIZATION, IMMUNOLOGIC; FACTOR IX; HEMOPHILIA B; HUMANS; IMMUNOLOGIC FACTORS; KINETICS; MALE; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 37849045281     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31815cf742     Document Type: Article

References (22)

1. Briet E, Reisner HM, Roberts HR. Inhibitors in Christmas disease. Prog Clin Biol Res. 1984;150:123-129.
2. DiMichelle DM, Kroner BL. The North American immune tolerance registry: practices, outcomes, outcomes predictors. Thromb Haemost. 2002;87:52-57.
3. Tengborn L, Hansson S, Fasth A, et al. Anaphylactoid reactions and nephritic syndrome - a considerable risk during factor IX treatment in patients with hemophilia B and inhibitors: a report on the outcome in two brothers. Haemophilia. 1998;4:854-859.
4. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997;19:23-27.
5. Matthew P, Young G. Recombinant factor RVIIa in paediatric bleeding disorders: a 2006 review. Hemophilia. 2006;12:457-472.
6. Fox RA, Neufeld EJ, Bennett CB. Rituximab for adolescents with hemophilia and high titer inhibitors. Haemophilia. 2006;12:218-222.
7. Mathias M, Khair K, Hann I, et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia. Br J Haematol. 2004;125:366-368.
8. Barnes C, Brewin T, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with hemophilia B by simple plasmapheresis and antigen exposure: progress report. Hemophilia. 2001;7:437-438.
9. Shibata M, Shima M, Misu H, et al. Management of hemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia. 2003;9:269-271.
10. Dioun AF, Ewenstein BM, Geha RS, et al. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol. 1998;102:113-117.
11. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol. 2006;6:476-481.
12. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol. 2006;6:271-277.
13. Naclerio RM, Mizrahi EA, Adkinson NF Jr. Immunologic observations during desensitizations and maintenance of clinical tolerance to penicillin. J Allergy Clin Immunol. 1983;71:294-301.
14. Sobotka AK, Dembo M, Goldstein B, et al. Antigen specific desensitization of human basophils. J Immunol. 1979;122:511-517.
15. Sullivan TJ. Antigen specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol. 1982;69:500-508.
16. Stark BJ, Earl HS, Gross GN, et al. Acute and chronic desensitization of penicillin allergic patients using oral penicillin. J Allergy Clin Immunol. 1987;79:523-532.
17. Graybill JR, Sande MA, Reinarz JA, et al. Controlled penicillin anaphylaxis leading to desensitization. South Med J. 1974;67:62-64.
18. Green D. The management of acquired hemophilia. Haemophilia. 2006;12(suppl 5):32-36.
19. Linde E, Ettinghausen CE, Voigt B, et al. First successful inhibitor elimination with a new protocol in a high responding hemophilia. A patient after failure of various immune tolerance induction regimens. Blood. 2001;98:534A.
20. Carcao M, St Louis J, Poon MC, et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia. 2006;12:7-18.
21. Mateo J, Badell I, Forner R, et al. Successful suppression using rituximab of a factor VIII inhibitor in a boy with severe congenital hemophilia: an example of a significant decrease of treatment costs. Thromb Haemost. 2006;95:386-387.
22. FDA. Rituxan warning. FDA Consum. 2007;4:3.